Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Chief Financial Officer | July 28, 2026 | July 30, 2026 |
| INNOVUS PHARMACEUTICALS, INC.INNV · Entity 151567 | VP, CFO | April 27, 2017 | April 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,743 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 25,000 · Balance 74,743 F1: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.
INNOVUS PHARMACEUTICALS, INC.
Report date April 27, 2017 · Filed April 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-04-27 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F3: These restricted stock units were granted pursuant to the Company's Amended and Restated 2016 Stock Incentive Plan. F1: Each restricted stock unit represents at settlement the right to receive one share of common stock. F2: The Reporting Person was granted a Restricted Stock Unit on April 27, 2018 of 1,200,000 shares that shall vest 1/3 on the first anniversary of the grant date and 2/3s over the next 8 quarters thereafter on an equal basis if the Reporting Person is still employed by the Company |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents at settlement the right to receive one share of common stock.
F2: The Reporting Person was granted a Restricted Stock Unit on April 27, 2018 of 1,200,000 shares that shall vest 1/3 on the first anniversary of the grant date and 2/3s over the next 8 quarters thereafter on an equal basis if the Reporting Person is still employed by the Company
F3: These restricted stock units were granted pursuant to the Company's Amended and Restated 2016 Stock Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:33 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025080 · rdgdoc.xml · nonDerivative · entry 1 Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,743 F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:12 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030645 · rdgdoc.xml · nonDerivative · entry 2 Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,743 F2 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:12 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 16,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030645 · rdgdoc.xml · nonDerivative · entry 1 Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,243 F1 · shares: The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus. Read SEC document |
| February 05, 2025 Filed Mar 4, 2025 00:22 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionRestricted Stock Units · Derivative | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000223 · form4.xml · derivative · entry 2 Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025. F1 · derivative.exercise_date: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025. F1 · derivative.expiration_date: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025. Read SEC document |
| February 05, 2025 Filed Mar 4, 2025 00:22 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionCommon Shares | 105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000912282-25-000223 · form4.xml · nonDerivative · entry 1 Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:10 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Shares | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-24-000798 · form4.xml · nonDerivative · entry 1 Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,895 F1 · shares: Represents shares of restricted stock which vest as follows: One-third on November 11, 2025; 1/12th of the original grant quarterly thereafter through November 11, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.